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Objectives: Dexamethasone has become the standard of care for severe coronavirus disease 2019 (COVID-
19), but its virological impact is poorly understood. The objectives of this work were to characterize the
kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration in the upper
respiratory tract (URT) and the antibody response in patients with (Dþ) and without (De) dexamethasone
treatment.
Methods: Data and biosamples from hospitalized patients with severe COVID-19, enrolled between 4th
March and 11th December 2020 in a prospective observational study, were analysed. SARS-CoV-2 virus
concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific immunoglobulins
A and G (IgA and IgG) were measured in serum samples using S1-ELISA.
Results: We compared 101 immunocompetent patients who received dexamethasone (according to the
inclusion criteria and dosage determined in the RECOVERY trial) to 93 immunocompetent patients with
comparable disease severity from the first months of the pandemic, who had not been treated with
dexamethasone or other glucocorticoids. We found no inter-group differences in virus concentration
kinetics, duration of presence of viral loads >106 viral copies/mL (Dþ median 17 days (IQR 13e24), De
19 days (IQR 13e29)), or time from symptom onset until seroconversion (IgA: Dþ median 11.5 days (IQR
11e12), De 14 days (IQR 11.5e15.75); IgG: Dþ 13 days (IQR 12e14.5), De 12 days (IQR 11e15)).
Conclusion: Dexamethasone does not appear to lead to a change in virus clearance or a delay in antibody
response in immunocompetent patients hospitalized with severe COVID-19. Barbara Mühlemann, Clin
Microbiol Infect 2021;▪:1
© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).iversit€atsmedizin Berlin, Department of Infectious Diseases and Respiratory Medicine, Augustenburger Platz 1, 13353
.
. Corman and Florian Kurth contributed equally.
r Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under
g/licenses/by-nc-nd/4.0/).
al., Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in
a prospective observational study, Clinical Microbiology and Infection, https://doi.org/10.1016/
B. Mühlemann et al. / Clinical Microbiology and Infection xxx (xxxx) xxx1.e2Introduction
Severe acute respiratory syndrome coronavirus type 2 (SARS-
CoV-2) infection has a clinical spectrum ranging from asymptom-
atic to severe disease [1]. Inflammation-mediated lung injury plays
a crucial role in progression to severe coronavirus disease 2019
(COVID-19). Glucocorticoids are widely used for treatment of in-
fectious and non-infectious diseases involving a dysregulated
immune response. In severe COVID-19, dexamethasone showed
beneficial effects when administered >7 days after symptom onset
[2] and became the standard of care [3]. However, the impact of
dexamethasone on viral concentration and the adaptive immune
response has not been well studied [4]. We analysed the impact
of dexamethasone on SARS-CoV-2 RNA kinetics and antibody
response in a prospective observational cohort of hospitalized
immunocompetent COVID-19 patients.
Materials and methods
Data collection was performed within the Pa-COVID-19
study, a prospective observational cohort study at Char-
itedUniversit€atsmedizin Berlin [5,6], approved by the local
ethics committee (EA2/066/20), conducted according to the
Declaration of Helsinki and Good Clinical Practice principles
(ICH 1996), and registered in the German andWHO international
clinical trials registry (DRKS00021688).
Patients were treated according to national guidelines. Treat-
ment with 6 mg dexamethasone orally or intravenously was
introduced as the standard of care shortly after the press release of
the RECOVERY trial on 16th June 2020 in patients fulfilling the
criteria of 7 days symptom duration and requiring at least sup-
plemental oxygen therapy (i.e. score 4 on the WHO scale for
clinical improvement [7]). This analysis includes patients enrolled
between 4th March and 11th December 2020 who fulfilled the
above-mentioned criteria in the absence of specific contraindica-
tions [2]. We excluded patients receiving non-standard doses of
dexamethasone or other glucocorticoids and with immunosup-
pression (at least one of the following: immunodeficiency,
immunosuppressive or cancer therapy within the previous
3 months, history of organ transplant, HIV infection, lymphoma, or
leukaemia).
SARS-CoV-2 RNA was measured by real-time (RT)-PCR in swabs
from the upper respiratory tract (URT) [8] and is given here as log10
RNA copies per 1 mL sampling buffer. In routine testing, a weekly
RT-PCR was performed, with test frequency sometimes increasing
towards the end of the isolation period. All patients with at least
one positive RT-PCR test result were included in the analysis. RNA
measurements taken up to 40 days after admission were included
for statistical analysis.
ELISA for the detection of immunoglobulins G and A (IgG and
IgA) to the S1 domain of the SARS-CoV-2 spike protein (S1-ELISA)
was performed once per week during hospital stay, as described
elsewhere [9]; a median of four measurements were performed per
patient. All patients with at least one reactive S1-ELISA test (optical
density (OD) ratio >1.1) were included in the analysis (n ¼ 174). S1-
ELISA OD ratios were capped at a value of 5. Outliersddefined as
patients who seroconverted or reached a threshold OD ratio of 5
after more than 30 daysdwere excluded (n ¼ 5). Distribution of
continuous variables is shown as median and interquartile range
(IQR). Differences of continuous variables between groups were
examined by ManneWhitney U test and of categorical variables
using c2 tests. Local regression (LOWESS) was used for the com-
parison of SARS-CoV-2 RNA kinetics. Analyses were conducted with
R (V3.6.1), JMP (V14.2.0), and statsmodels (V0.12.0) in Python
(V3.7.9).Please cite this article as: Mühlemann B et al., Impact of dexamethaso
hospitalized COVID-19 patients: results from a prospective observationa
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We identified 216 patients in our cohort with an indication for
dexamethasone treatment according to current national guide-
lines; of these patients 202 were not immunosuppressed and were
included in the analysis. One hundred and one patients received
dexamethasone treatment (Dþ) of 6 mg/day orally or intravenously
for a median duration of 10 days (IQR 8.5e11), initiated at a median
of 7 days (IQR 5e10) after symptom onset or 1 day (IQR 0e2) after
hospital admission; 93 patients, mostly hospitalized before June
2020, did not receive dexamethasone or other glucocorticoids (De,
Supplementary Material Fig. S1). Eight patients received other
glucocorticoids or different daily doses of dexamethasone andwere
excluded. We found no statistically significant differences between
clinical baseline characteristics, including duration of symptoms
until hospital admission, age, gender, presence of comorbidities,
or level of respiratory support at admission in the groups
(Supplementary Material Tables S1 and S2).
Virus concentration
SARS-CoV-2 RNA concentration kinetics in the URT did not differ
between patient groups (Fig. 1A), even though De patients had
lower RNA concentrations throughout the study than Dþ patients
(Supplementary Material Fig. S2). Similarly, no difference was seen
when excluding patients (n ¼ 18) undergoing antiviral treatment
(Supplementary Material Table S1). We also found no evidence for
differences in the time from symptom onset to the last test with a
viral load >106 viral copies/mL between patient groups (Dþ median
17 days (IQR 13e24), De median 19 days (IQR 13e29), p 0.37)
(Fig. 1B).
Antibody response
Analysis of time to seroconversion was feasible for 50 patients
showing a non-reactive S1-ELISA result upon inclusion into the
study. There was no difference in time from symptom onset to first
reactive IgA or IgG S1-ELISA test (i.e. seroconversion) between Dþ
and De patients (median days to IgA seroconversion 11.5 (IQR
11e12) versus 14 (IQR 11.5e15.75), respectively, p 0.47; median
days to IgG seroconversion 13 (IQR 12e14.5) versus 12 (IQR 11e15),
respectively, p 0.70. Figs. 2A,B). Seventy-nine percent of patients
reached IgA and IgG OD ratios 5 within 20 days after symptom
onset. There was no difference between Dþ and De patients in time
from symptom onset to the first test with an OD ratio 5 (median
days from symptom onset to first IgA test with OD ratio 5, 13 (IQR
10e16) versus 13 (IQR 11e15.5), respectively, p 0.76; median days
from onset to first IgG test with OD ratio 5, 15 (IQR 13e18) versus
15 (IQR 12e16), respectively, p 0.20) (Figs. 2C,D).
Discussion
The introduction of dexamethasone for the treatment of severe
COVID-19 raised concerns regarding possible subsequent delay in
virus clearance, based on observational studies [10] and data on
glucocorticoid therapy in other respiratory virus infections,
including SARS-CoV, MERS-CoV [11], and influenza A [12]. Accurate
analysis of the impact of dexamethasone on virus clearance and
adaptive immune response in COVID-19 would require randomized
controlled trials. As collection of virological and laboratory datawas
not included in the published RECOVERY trial protocol [2], this
approach seems beyond reach. Most studies available to date are
based on heterogenous medication regimens and show no influ-
ence of corticosteroids on virus clearance and antibody response in
COVID-19 [3,13,14].ne on SARS-CoV-2 concentration kinetics and antibody response in
l study, Clinical Microbiology and Infection, https://doi.org/10.1016/
Fig. 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration kinetics and shedding. (A) Virus concentration over time in upper respiratory tract (URT)
samples in two groups of hospitalized COVID-19 patients with comparable disease severity (WHO score  4), Dþ patients in orange and De in blue. Bold lines and shaded areas
indicate the LOWESS fit (smoothing parameter 0.5) and 95% confidence intervals (calculated from 1000 bootstrap replicates of 90 samples, corresponding to ~90% of the full dataset)
for the two groups. The grey area indicates the typical time span during which dexamethasone was administered (a median of 1e11 days after admission). (B) Duration of shedding
was measured as the time from symptom onset to the last PCR test with a viral load >106 viral copies/mL for Dþ and De patients. Median shedding duration: Dþ median 17 days (IQR
13e24); De median 19 days (IQR 13e29), p 0.37 (ManneWhitney U test). During their time in hospital, Dþ patients had a median of three tests (IQR 2e6), a median of 4 days (IQR
2e7) apart, and De patients had a median of five tests (IQR 3e8), a median of 4 days (IQR 2e7) apart.
Fig. 2. IgG and IgA S1-ELISA results. (A,B) Time to seroconversion. Time to seroconversion is measured as the time from symptom onset to a reactive S1-ELISA test that is preceded
by a non-reactive S1-ELISA test. (A) IgA, median duration to seroconversion: Dþ 11.5 days (IQR 11e12); De 14 days (IQR 11.5e15.75). Seroconversion could be observed in six Dþ
patients and six De patients who were included into the study with a non-reactive IgA S1-ELISA result. (B) IgG, median duration to IgG seroconversion, Dþ 13 days (IQR 12e14.5), De
12 days (IQR 11e15). For IgG, 23 Dþ patients and 15 De patients were included into the study with a non-reactive IgG S1-ELISA and later seroconverted. (C, D) Time from symptom
onset to the first test reaching the threshold OD ratio 5. Only patients with a first test taken no more than 20 days after symptom onset were included. (C) IgA, median duration
from symptom onset to first IgA S1-ELISA test with OD ratio 5, Dþ 13 days (IQR 10e16), De 13 days (IQR 11e15.5). (D) IgG, median duration from symptom onset to first IgG S1-
ELISA test with OD ratio 5, Dþ 15 days (IQR 13e18), De 15 days (IQR 12e16). Outliersddefined as patients with >30 days until seroconversion or >30 days to reach the threshold
OD ratio of 5dwere excluded (n ¼ 5).
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cohort study we found no difference in SARS-CoV-2 RNA kinetics
or humoral immune response in two comparable groups ofPlease cite this article as: Mühlemann B et al., Impact of dexamethason
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with or without dexamethasone. We observed a shorter duration
of hospital stay and a trend towards reduced progression toe on SARS-CoV-2 concentration kinetics and antibody response in
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yet this observational data may be influenced by factors such as a
more strained healthcare system in the second pandemic wave.
A limitation to our study is the relatively small sample size,
particularly with regard to biosamples before seroconversion. We
could not adjust for demographic and clinical parameters that may
influence antibody kinetics [9].
Our results indicate that standard-dose dexamethasone treat-
ment in severe COVID-19 casesdinitiated after the peak of SARS-
CoV-2 replication during the first week [15]ddoes not lead to
slower virus clearance or antibody response in immunocompetent
patients, a finding of importance to clinical management, public
health authorities, and the scientific community.
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